We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Akero Therapeutics

News List

Akero Therapeutics Receives European Medicines Agency Priority Medicines (PRIME) Designation for Efruxifermin (EFX) in NASH prnewswire
October 21, 2020
Akero Therapeutics, Inc. announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to efruxifermin (EFX), an investigational FGF21 analog for the treatment of NASH.
Akero Therapeutics Initiates AKR-001 Phase 2a Clinical Trial for NASH americanpharmaceuticalreview
May 30, 2019
Akero Therapeutics announced it has screened the first patient for its Phase 2a clinical trial evaluating AKR-001, the company's lead product candidate for the treatment of NASH.
NASH-focused Akero Therapeutics adds another $70M to the bank fiercebiotech
December 26, 2018
Just six months after bagging a $65 million series A, Akero Therapeutics is at it again. The company has reeled in $70 million in its B round that will push its lead asset.....